| Chuang SE |
------>authors3_c=??? ------>paper_class1=6 ------>Impact_Factor=None ------>paper_class3=0 ------>paper_class2=0 ------>vol= ------>confirm_bywho=ncchang ------>insert_bywho=gminlai ------>Jurnal_Rank=None ------>authors4_c= ------>comm_author= ------>patent_EDate=2017-06-10 00:00:00 ------>authors5_c= ------>publish_day=11 ------>paper_class2Letter=None ------>page2= ------>medlineContent= ------>unit=E0109 ------>insert_date=20090402 ------>iam=3 ------>update_date=None ------>author=??? ------>change_event=4 ------>ISSN= ------>authors_c=??? ------>score=11 ------>journal_name= ------>paper_name=?????????? (Cancer therapy) ------>confirm_date=20090710 ------>tch_id=097095 ------>pmid=19924794 ------>page1= ------>fullAbstract=BACKGROUND:: Salivary gland cancers are rare, histologically diverse, and varied in their biologic behavior and responsiveness to systemic therapy. To the authors~ knowledge, there currently is no standard chemotherapy for these tumors, but cisplatin-based regimens are often used. This phase 2 trial evaluated the combination of gemcitabine with cisplatin (carboplatin in those with protocol-defined contraindications to cisplatin). METHODS:: Fit, consenting adult patients had advanced, metastatic, or locoregionally recurrent salivary gland cancer (any histologic subtype) that was not suitable for radiation or surgery. Therapy was comprised of gemcitabine at a dose of 1000 mg/m(2) administered intravenously on Days 1 and 8, and cisplatin at a dose of 70 mg/m(2) on Day 2, of a 21-day cycle. If carboplatin was substituted, it was administered on Day 1, targeted to an area under the concentration-time curve of 5 mg/mL/s. Response was assessed every 2 cycles according to Response Evaluation Criteria In Solid Tumors. Patients received up to 6 cycles. The primary endpoint was objective response. A 2-stage design was used, with a response rate of 45% required to declare the regimen active. RESULTS:: Thirty-three eligible patients were enrolled, of whom 30 were response evaluable. Eight objective responses were observed (1 complete and 7 partial) for a response rate of 24% (95% confidence interval, 11-42%), with responses observed in all histologic subtypes. Toxicity was within that expected for this combination. CONCLUSIONS:: This regimen did not meet the predefined criteria to be declared active in advanced salivary gland cancers. Enrollment of patients with these rare cancers into well-designed clinical trials remains an urgent priority. Cancer 2010. (c) 2009 American Cancer Society. ------>tmu_sno=None ------>sno=21761 ------>authors2=Yao CJ ------>authors3=Lai GM ------>authors4= ------>authors5= ------>authors6= ------>authors6_c= ------>authors=Chuang SE ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c=??? ------>publish_area=0 ------>updateTitle=A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a Trial of the NCIC Clinical Trials Group. ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=???? ------>no= ------>patent_SDate=2008-06-11 00:00:00 ------>update_bywho=None ------>publish_year=2008 ------>submit_flag=None ------>publish_month=6 |